PT - JOURNAL ARTICLE AU - Gupta, Alind AU - Chan, Kelvin AU - Gomes, Manuel AU - Duffield, Stephen AU - Ramagopalan, Sreeram AU - Kent, Seamus AU - Subbiah, Vivek AU - Cheung, Winson AU - Bendavid, Eran AU - Arora, Paul TI - Transportability of patient outcomes from a US clinical trial to real-world populations - a case study using Lung-MAP S1400I (NCT02785952) AID - 10.1101/2024.05.25.24307916 DP - 2024 Jan 01 TA - medRxiv PG - 2024.05.25.24307916 4099 - http://medrxiv.org/content/early/2024/05/27/2024.05.25.24307916.short 4100 - http://medrxiv.org/content/early/2024/05/27/2024.05.25.24307916.full AB - Background The external validity of results from clinical trials to routine clinical practice is often questioned. This is sometimes because certain real world patient groups are excluded or underrepresented in clinical trials, or because standards of care in trials are different from those in real-world populations globally. This lack of external validity of trial results manifests as an efficacy-effectiveness gap. In this study, we aim to address the question of whether it is possible to extend results from a clinical trial to real-world populations across different countries. To do this, we use the Lung-MAP nonmatch sub-study S1400I trial (NCT02785952) as a case study.Setting Squamous cell lung carcinoma is a subtype of non-small cell lung cancer (NSCLC) accounting for 25-30% of cases. Compared to other NSCLC subtypes such as adenocarcinoma, the presence of actionable genetic variants is less common and there are fewer targeted therapies available for advanced/metastatic NSCLC (aNSCLC) of squamous subtype. Patients with squamous aNSCLC who progress on front-line chemotherapy commonly receive immunotherapy using immune checkpoint inhibitors such as nivolumab. The Lung-MAP nonmatch sub-study S1400I (NCT02785952) compared overall survival (OS) in patients with recurrent/stage IV squamous NSCLC randomized to receive either nivolumab monotherapy or nivolumab + ipilimumab combination therapy and found no significant difference in mortality rates between these groups. The trial included patients from the United States only.Objectives The goal of this study is to evaluate the transportability of results from NCT02785952 in United States patients to real-world populations in the United States, Germany, France, England and Japan. Using individual-level data for OS from NCT02785952, we will adjust for baseline characteristics from published studies of real-world populations in these countries and benchmark the predicted OS against Kaplan-Meier estimates reported by these studies for patients with squamous cell aNSCLC treated with nivolumab. Sensitivity analyses for unmeasured prognostic variables will be performed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was performed using data from the NCTN Data Archive of the National Cancer Institute's (NCI's) National Clinical Trials Network (NCTN). Data were originally collected from clinical trial NCT number NCT02785952. Data can be accessed through Project Data Sphere's Data Sharing Platform.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData can be requested through Project Data Sphere's Data Sharing Platform.